1. Home
  2. JFR vs CDNA Comparison

JFR vs CDNA Comparison

Compare JFR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.62

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$22.33

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
CDNA
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
JFR
CDNA
Price
$7.62
$22.33
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$28.00
AVG Volume (30 Days)
623.1K
558.6K
Earning Date
01-01-0001
04-28-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
$48,324,000.00
Revenue This Year
N/A
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
N/A
$455.30
Revenue Growth
N/A
18.93
52 Week Low
$7.16
$10.96
52 Week High
$8.59
$23.24

Technical Indicators

Market Signals
Indicator
JFR
CDNA
Relative Strength Index (RSI) 56.81 60.77
Support Level $7.44 $15.80
Resistance Level $7.99 $22.89
Average True Range (ATR) 0.05 0.94
MACD 0.01 0.09
Stochastic Oscillator 69.39 77.30

Price Performance

Historical Comparison
JFR
CDNA

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: